- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed shareholders approve demerger
Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while
Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while theenergy unit will be called Hafslund ASA. Nycomed shares will betraded on the Oslo, London, and Copenhagen exchanges, while NycomedAmerican Depository Receipts will be listed on the New York StockExchange under the symbol "NYD."
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
